Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush

Key Points

• Wedbush reissued its "outperform" rating for Bicara Therapeutics (NASDAQ:BCAX) with a price target of $30.00, suggesting a potential upside of 183.42% from its previous close.
• Despite positive ratings from some analysts, the stock experienced a disappointing EPS report of ($0.68), which was below the consensus estimate of ($0.40).
• Institutional interest has intensified, with Red Tree Management acquiring a new position valued at $55.23 million and Vestal Point Capital increasing its holdings by 290% during recent quarters.

Wedbush reissued their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX - Free Report) in a report issued on Tuesday morning,RTT News reports. They currently have a $30.00 target price on the stock. Wedbush also issued estimates for Bicara Therapeutics' Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($2.25) EPS and FY2028 earnings at ($2.16) EPS.

A number of other brokerages have also issued reports on BCAX. Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price on the stock in a research report on Friday, May 23rd. HC Wainwright cut their target price on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, Wall Street Zen lowered Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Bicara Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $31.86.

Bicara Therapeutics Price Performance

Shares of BCAX stock traded up $0.23 during trading on Tuesday, hitting $11.64. 184,203 shares of the stock traded hands, compared to its average volume of 299,236. The firm has a market capitalization of $635.08 million and a P/E ratio of -3.67. The firm's fifty day moving average price is $10.43 and its 200-day moving average price is $11.95. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.04. As a group, equities research analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors have recently modified their holdings of BCAX. Vanguard Group Inc. grew its stake in shares of Bicara Therapeutics by 1,457.9% in the fourth quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock worth $18,997,000 after acquiring an additional 1,020,528 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Bicara Therapeutics by 8,768.5% in the fourth quarter. JPMorgan Chase & Co. now owns 64,740 shares of the company's stock worth $1,128,000 after acquiring an additional 64,010 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Bicara Therapeutics by 859.4% during the fourth quarter. Geode Capital Management LLC now owns 466,642 shares of the company's stock worth $8,131,000 after purchasing an additional 418,003 shares in the last quarter. Wells Fargo & Company MN acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth $175,000. Finally, Invesco Ltd. acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth $267,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.